We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. With our headquarters in the UK, we have a wide geographical reach. We have offices in more than 115 countries, major research centres in the UK, USA, Spain, Belgium and China and an extensive manufacturing network with 87 sites globally.
GSK Vaccines is the division of the GlaxoSmithKline group responsible for the development and production of vaccines. Research is vitally important to the success of our business, and we spent just under £4 billion in 2012 in our search to develop new medicines, vaccines and innovating consumer products. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.
Our vaccine business is one of the largest in the world, with nearly 900 million doses distributed to 170 countries in 2012. We produce pediatric and adult vaccines to prevent a range of infectious diseases including: hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis.
GSK’s vaccines business puts the customer at the heart of everything we do. We define our vaccines mission as “Protecting . Human . Kind”:
Institut Mérieux is committing its experience in industrial biology to serve medicine and public health across the globe. Challenging biology, improving public health To fight against infectious diseases and cancers, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, food safety and nutrition. Throughout the world, it aims to make these solutions accessible to the greatest number of people. It has in particular created IMAccess, a company devoted to diagnostics for developing countries and working biology without borders Its three bio-industrial companies: bioMérieux, Transgene, Mérieux NutriSciences, working closely with its entities devoted to innovation, such as ABL Inc. and Mérieux Développement, have enabled major advances in medicine and public health. Institut Mérieux employs close to 10,000 people committed to global public health. It is present in over 40 countries, and generates sales of over €1.4 billion.
Institut Mérieux is a funding Partner of the Master LIVE.
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. We have the expertise in both veterinary pharmaceutical products and vaccines (biologicals) for companion and production animals. Merial has 3 global R&D centers and 10 regional sites in 10 countries to support global and local product needs.
Merial employs approximately 6000 people and operates in more than 150 countries worldwide. Its 2012 sales were €2.2 billion ($2.8 billion).
Merial is a Sanofi company.
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. The development of vaccines to prevent serious disease is an extraordinary story of medical achievement - one in which Pfizer and its 'legacy' companies have played a critical role for more than a century. Today, Pfizer is helping to usher in a new era of vaccine innovation - both to prevent and treat disease. As the global leader in pneumococcal disease prevention, Pfizer will continue to push the boundaries of innovation to pursue the next scientific breakthrough for the prevention of pneumococcal disease. In addition, Pfizer is developing vaccines that target meningococcal serogroup B disease - which is an important cause of meningitis and bloodstream infections for which no vaccine is currently available, and a vaccine for Staphylococcus aureus - the leading cause of hospital-acquired infections.
Sanofi Pasteur, the vaccines division of Sanofi, is the largest company in the world devoted entirely to human vaccines. Our driving goal is to protect people from infectious diseases by creating safe and effective vaccines. Our company offers the broadest range of vaccines in the world, providing protection against 20 bacterial and viral diseases. We distribute more than 1 billion doses of vaccine each year, making it possible to vaccinate more than 500 million people across the globe.
Sanofi Pasteur is a funding Partner of the Master LIVE.
Based on the corporate philosophy of "Takeda-ism" (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”
The network of the Takeda group spans over 70 countries and regions worldwide, in Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific Region. Takeda's pharmaceutical products are marketed in around 100 countries worldwide, including partnerships (marketing alliance partners).The Takeda Group consists 158 companies, including the parent company submitting these consolidated financial statements, 138 consolidated subsidiaries and 19 affiliates accounted for by the equity method.